<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04367090</url>
  </required_header>
  <id_info>
    <org_study_id>BLTN-Ig</org_study_id>
    <nct_id>NCT04367090</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Study of Pyrotinib and Docetaxel in Combination With Trastuzumab in Patients With HER2 Metastatic Breast Cancer</brief_title>
  <official_title>An Open, Single-arm and Fixed-sequence Pharmacokinetic Study of Pyrotinib and Docetaxel Plus Trastuzumab in Patients With HER2 Positive Recurrent or Metastasis Breast Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to study the pharmacokinetics of pyrotinib and
      docetaxel plus Trastuzumab in HER2 Positive MBC.

      The secondary objective of the study is to evaluate the safety and efficacy (ORR) of
      pyrotinib and docetaxel plus Trastuzumab in HER2 Positive MBC.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2020</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic parameter: Cmax of pyrotinib and docetaxel</measure>
    <time_frame>Approximately 2 months</time_frame>
    <description>Peak Plasma Concentration (Cmax) of pyrotinib</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic parameter: AUC of pyrotinib and docetaxel</measure>
    <time_frame>Approximately 2 months</time_frame>
    <description>Area under the plasma concentration versus time curve (AUC) of pyrotinib and docetaxel</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ORR</measure>
    <time_frame>Approximately 17 months</time_frame>
    <description>Objective Response Rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AEs+SAEs</measure>
    <time_frame>Approximately 17 months</time_frame>
    <description>Adverse Events and Serious Adverse Events</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">14</enrollment>
  <condition>Metastatic Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Pyrotinib and docetaxel plus trastuzumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel, trastuzumab</intervention_name>
    <description>Docetaxel and trastuzumab once per cycle</description>
    <arm_group_label>Pyrotinib and docetaxel plus trastuzumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pyrotinib</intervention_name>
    <description>Pyrotinib 400 mg orally daily</description>
    <arm_group_label>Pyrotinib and docetaxel plus trastuzumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pyrotinib, docetaxel and trastuzumab</intervention_name>
    <description>Pyrotinib 400 mg orally daily plus docetaxel and trastuzumab</description>
    <arm_group_label>Pyrotinib and docetaxel plus trastuzumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. HER2 positive recurrent or metastasis breast cancer.

          2. Patients with measurable disease are eligible.

          3. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.

          4. Adequate organ function.

          5. Signed, written inform consent obtained prior to any study procedure.

        Exclusion Criteria:

          1. Patients received more than 1 line of chemotherapy, or more than 1 line of endocrine
             therapy, or received targeted therapy and immunotherapy in the phase of recurrence /
             metastasis.

          2. History of HER tyrosine kinase inhibitors or monoclonal antibody for breast cancer in
             any treatment setting，except trastuzumab used in the neo-adjuvant or adjuvant setting.

          3. Assessed by the investigator to be unable receive systemic chemotherapy.

          4. History of other malignancy within the last 5 years，except for carcinoma in situ of
             cervix，basal cell carcinoma or squamous cell carcinoma of the skin that has been
             previously treated with curative intent.

          5. Pregnant or lactating women，or for women of childbearing potential unwilling to use a
             highly-effective contraception during of the study treatment and for at least 7 months
             after the last dose of study treatment.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 24, 2020</study_first_submitted>
  <study_first_submitted_qc>April 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 29, 2020</study_first_posted>
  <last_update_submitted>April 26, 2020</last_update_submitted>
  <last_update_submitted_qc>April 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

